About the Journal
EDITOR-IN-CHIEF: Giuseppe Tonini, Director of Medical Oncology, University Campus Bio-Medico, Italy
Commissioning Editor: David Grech
Production Manager: Claire Summerfield
2013 Impact factor 5.432
ISSN: 1354-3784 (print), 1744-7658 (electronic)
- Investigational therapies for the treatment of spinal muscular atrophy
- Investigational therapies targeting lymphocyte antigens for the treatment of non-Hodgkin’s lymphoma
- Trends in the early investigational drug development and areas for improvement
- Ranolazine for the treatment of atrial fibrillation
Gian Marco Rosa,
- Cebranopadol: a first-in-class potent analgesic agent with agonistic activity at nociceptin/orphanin FQ and opioid receptors
Expert Opinion publishes a Themed Issue on Investigational Drugs for Affective DisordersMarch 16, 2015EOID is delighted to highlight this April’s Themed Issue on “Investigational Drugs for Affective Disorders”. The journal brings together the opinions of some of the leading experts in the field on the potential therapies of the future for a number of disorders including depression, bipolar disorder and obsessive-compulsive disorder.
Developments in treating insomnia – our Editorial Highlight for MarchMarch 6, 2015The editorial office are delighted to present ”
Current Phase II investigational therapies for insomnia” by
N Zisapel as our Editorial highlight for the
March issue of
Expert Opinion on Investigational Drugs.
Expert Opinion on Biological Therapy publishes themed issue on Gene Therapy with Professor Ryuichi Morishita [Includes FREE content]March 4, 2015
This month, Expert Opinion on Biological Therapy has published a themed issue ‘New Era in Gene Therapy: End of the Beginning’ with guest editor Professor Ryuichi Morishita.
Expert Opinion on Orphan Drugs publishes a themed issue in association with EURORDIS and NORDNovember 27, 2022This month,
Expert Opinion on Orphan Drugs has published a themed issue in partnership with EURORDIS (European Organisation for Rare Diseases) and NORD (National Organization for Rare Disorders). The purpose of this themed issue is to improve the scientific community’s understanding of the important issues surrounding rare diseases and the impact they have on the lives of patients.
December’s Editorial Highlight: An overview of discontinued anti-diabetic drugs for 2013November 27, 2022We are happy to bring to your attention to this month’s Discontinued Drug Perspective on 2013’s
antidiabetic drugs, written by
MS Hedrington and
SN Davis from the University of Maryland as our Editorial Highlight. Click on the link above for more information…
A snapshot of potential therapies for treating female sexual dysfunctionNovember 7, 2022There have been calls in the media and from various sufferers of female sexual dysfunction for more to be done in terms of developing new therapeutics. Expert Opinion investigates…
Our Editorial highlight for November: potential treatment options for chronic constipationOctober 28, 2022The editorial office is happy to present this interesting article on phase II drugs for
chronic constipation as our
editorial highlight for the November issue of
Expert Opinion on Investigational Drugs published by
S Mozaffari et al. Please see inside for more details…
Cocaine Dependence Treatments: An Unmet Clinical NeedOctober 9, 2022Substance abuse and
addiction is a hugely problematic issue. Cocaine, one such addictive substance, currently has
no-FDA approved therapeutic and therefore has an unmet critical need. Efforts to meet this need have led to the development of a number of drugs that are currently in
Phase II clinical trials. A recent article in
Expert Opinion on Investigational Drugs reviews this area…
World Mental Health Day 2022: focus on schizophreniaOctober 8, 202210th October 2022 is World Mental Health Day and this year’s focus is schizophrenia. In recent issues, Expert Opinion journals have considered the novel targets for future treatments of schizophrenia. Details of how to access full copies of these papers are included in this story.
What you need to know when publishing with us – TOP TIPSOctober 2, 2022Every author wants to publish their paper quickly. Read here for our top tips to speed up the process and some interesting info about the benefits of publishing with the Expert Collection.
October 2022 is Breast Cancer Awareness month.October 1, 2022
During the month of October the Expert Collection are making some of our latest articles on breast cancer FREE in order to raise awareness of this disease and help provide healthcare professionals access to the latest research in this field.
Our Editorial Highlight for October – Zucapsaicin for treating neuropathic painSeptember 25, 2022We at the editorial office are happy to highlight our fascinating drug evaluation on
zucapsaicin for the potential treatment of
neuropathic pain as our
editorial highlight for
October. The article is written by Kinga Salat et al of the Jagiellonian University, Krakow, Poland.
Nalmefene hydrochloride (Selincro) launched in France: a new treatment for alcohol dependenceSeptember 19, 2022Biotie Therapies announced on the 19th of September that its partner
Lundbeck A/S has brought the
alcohol dependence therapy
nalmefene hydrochloride to the market in
France. This news will be of considerable interest given the lack of efficacious therapeutics currently available for the treatment of alcohol dependence.
Expert Opinion on Investigational Drugs recently published an article highlighting the latest potential therapeutic options.
Can you vaccinate against cocaine addiction? Our Experts review the current researchSeptember 4, 2022
Cocaine addiction is a major problem around the world, but can you vaccinate against it, prime the immune system to respond?
In the September issue of Expert Opinion on Biological Therapy, Frank Orson, Thomas Kosten and their colleagues review the most recent human clincial trials and disucss the implications of cociane pharmacokinetics for robuse vaccine antibody responses and further vaccine development – read more here
The alcoholic gene: future implicationsAugust 29, 2022The Scripps Research Institute have recently presented evidence which suggests that there is a gene that plays a key role in a person’s susceptibility to alcoholism.
Expert Opinion on Investigational Drugs looks at this recent news and the broader issue of alcoholism therapy.
What’s new in amyotrophic lateral sclerosis treatment?August 26, 2022As the amyotrophic lateral sclerosis (ALS) ice bucket challenge takes social media by storm, Expert Opinion has reviewed future therapy options managing and treating this neurodegenerative disease.
Interested in the early development of acute myeloid leukemia therapeutics?August 1, 2022Do you have an interest in the development of novel therapeutics for the treatment of acute myeloid leukemia?
Expert Opinion on Drug Discovery and
Expert Opinion on Investigational Drugs present some of the recent articles published by us on this fascinating field.
Recently on Expert Opinion: Attention deficit hyperactivity disorder therapeuticsJuly 22, 2022
Get the latest developments on new and potential Attentional deficit hyperactivity disorder (ADHD) therapies from Expert Opinion with four recently published drug evaluations. Spanning three Expert Opinion journals, we provide evaluations on sofinicline, guanfacine, methyphenidate and edivoxetine.
Developing diabetic nephropathy therapies: what’s new?July 18, 2022This month, Concert Pharmaceuticals Inc released positive word over the recent
phase II clinical trial on the drug CTP-499 for the treatment of
diabetic nephropathy, a condition that has become increasingly prevalent as a result of the diabetes global epidemic. This new coincides with a recent article published by
Expert Opinion on Investigational Drugs.
Slow progression with amyotrophic lateral sclerosisJuly 9, 2022
In 1939, Lou Gehrig shocked the world of baseball when he announced that he had been diagnosed with the fatal neurodegenerative disease amyotrophic lateral sclerosis. 75 years on, small but important progress is being made in the battle to manage and treat this incurrable disease.
The challenge of targeted therapies for gastric cancer – Our July editorial highlightJuly 8, 2022We are happy to highlight “The challenge of targeted therapies for gastric cancer patients: the beginning of a long journey” from the
July issue of
Expert Opinion on Investigational Drugs.
Expert Collection on colorectal cancerJuly 3, 2022Taking you from preclinical development, therapeutic targeting and biomarkers, through epigenetics and finding the right treatments, to the latest drugs on the market and their safety –
Expert Opinion and
Expert Review journals takes a look at colorectal cancer!
2013 Top 10 diabetes drugs in the Expert CollectionsJune 25, 0014Diabetes is one of the most prevelant diseases in the western world, we highlight some recent publications from the
Expert Collections journals you might find interesting.
Our June Editor’s Pick: Investigational Therapies for pancreatic adenocarcinomaMay 29, 2022We are happy to announce that the article entitled
“Brief overview of selected approaches in targeting pancreatic adenocarcinoma”, written by
WR Samore and
CS Gondi ias our Editor’s Pick for our recent
June issue of
Expert Opinion on Investigational Drugs.
What are we reading in the Expert Collections this week?May 12, 2022
With all of space and time to explore, what caught our eye this week?
Questions we’re asking include how do we move forward ethically with tissue enginnering?
What effect does chemotherapy have on female sex drive?
How can you treat cocaine addction?
And finally, what’s next in the fight for polio vaccination?
Find out more…..
A look at novel therapies for ovarian cancer – our Editor’s pick for MayMay 2, 2022We are happy to inform you that “Novel therapies, including enzastaurin, in the treatment of ovarian cancer” by I Vergote as our editor’s pick for our May issue of Expert Opinion on Investigational Drugs.
Melanoma treatment – BRAF or non-BRAF therapies? Chemical versus biological drugs? Find out more!April 17, 0014This month Expert Opinion have delved into the various treatments available for melanoma
Closing in on a cure for Hepatitis C?April 17, 2022Gilead Sciences announced at the European Association for the Study of the Liver Conference, in London that its two-drug treatment of sofosbuvir and ledipasvir demonstrated a cure rate of 94 per cent. These recent developments coincide with our recent drug evaluation on ledipasvir published last month.
Investigational Drugs for Diabetic Nephropathy – Our April Editorial HighlightMarch 27, 2022For this month’s issue of Expert Opinion on Investigational Drugs, we are happy to highlight Hajhosseiny et al.’s review article on the emerging therapeutic agents of diabetic nephropathy.
WT1 vaccination in acute myeloid leukemia – March’s Editorial Highlight.March 14, 2022In our March issue of Expert Opinion on Investigational Drugs, we are happy to present the drug evaluation of the WT1 vaccination in acute myeloid leukemia as this month’s Editorial Highlight.
The Expert Collection profiles 15 of the top newly launched drugsMarch 13, 2022A list of the ‘Top 15 Drug Launch Superstars’ was recently put together by Fierce Pharma. The Expert Collection has papers covering each of these drugs. The drugs on the list have all been successfully launched and approved and cover a range of indications
First half of the First-in-Class cross-series themed issue available now!February 17, 2022First-in-Class drugs and their novel mechanisms of action are the focus of the first Expert Opinion and Expert ReviewsCross-series themed issue. All articles will be published in their respective journals between January and April 2022 so half of them are already available!
Our Editorial Highlight for the February issue of Expert Opinion on Investigational DrugsFebruary 10, 2022The editorial team is happy to highlight the article “Combating multidrug-resistant Gram-negative bacterial infections” by ZQ Xu, MT Flavin and J Flavin as our editorial highlight for the February issue of Expert Opinion on Investigational Drugs.
DP2 receptor antagonists and asthma: A status update – Our Editorial Highlight for January 2022January 20, 2022I am delighted to present to you Peter Norman’s review article on “Update on the status of DP2 receptor antagonists; from proof of concept through clinical failures to promising new drugs” as our Editorial Highlight for the January issue of Expert Opinion on Investigational Drugs.
Expert Opinion and Expert Reviews are now on facebook!December 18, 2013The Expert Opinion & Expert Reviews journals are now on facebook! Click here to visit our page and ‘LIKE’ us to keep updated of the newest articles and hottest news!
Expert Opinion posts TWO articles on Rho kinase inhibitors early online!December 6, 2013If you want to know more about Rho kinase inhibitors, look no further! Expert Opinion on Therapeutic Patents and Expert Opinion on Investigational Drugs have both recently posted articles on these compounds from different points of view.
Editor-in-Chief, Professor Giuseppe Tonini, chooses Metformin editorial as his Editor’s Pick!December 4, 2013Editor-in-Chief of Expert Opinion on Investigational Drugs, Professor Giuseppe Tonini, has chosen ‘Metformin: an old drug with new potential’ by Joud Hajjar, Mouhammed Amir Habra & Aung Naing as his Editor’s Pick for December!
Sunitinib’s potential new role in ovarian cancer – online now in the December issue of Expert Opinion on Investigational DrugsDecember 2, 2013The Publisher would like to recommend this Drug Evaluation from Umberto Leone Roberti Maggiore, Mario Valenzano Menada, Pier Luigi Venturini & Simone Ferrero on “The potential of sunitinib as a therapy in ovarian cancer“ as a highlight of the December issue of Expert Opinion on Investigational Drugs.
This Week in Expert Opinion…November 22, 2013This week in the Expert Opinion journals we look at therapeutic targets and methods of targeted therapy from different points of view and stages of drug development.
Our November Issue Editorial Highlight: Is Metformin useful in the treatment of Lung Cancer?November 7, 2013The editorial team are happy to select “Metformin in lung cancer: rationale for a combination therapy” as their editorial highlight from their November issue of Expert Opinion on Investigational Drugs. please click the link for more details.
Expert Opinion covers two of the top 10 medical innovations of 2022!November 6, 2013Each year the Cleveland Clinic in Ohio announces its predictions for the top 10 medical innovations for the coming year and Expert Opinion is ahead of the game!
This Week in Expert OpinionOctober 22, 2013This Week in the Expert Opinion journals, we look into new and not-so-new therapies for cancer, the pharmacokinetics of a common contraceptive, and wonder what special considerations are needed for clinical trials of orphan drugs. Find out more here…
New HIV strain spreading rapidly in Russia: New Drugs in DemandOctober 18, 2013A number of periodicals have recently reported on the growing concern, in Russia, at the rate which HIV is spreading as a result of a new viral strain. These concerns have, amongst other things, highlighted the increasing demand for new, more effective, therapies to better combat HIV infection….(continued).
Editor’s Pick for October 2013October 9, 2013We are happy to announce that our Editor in Chief has selected the article “Targeting tyrosine-kinases in ovarian cancer” as his editor’s pick for the October issue of Expert Opinion on Investigational Drugs
First-in-Class Drugs – pioneers with great potential!August 16, 2013The FDA defines a First-in-Class drug as one which uses a new and unique mechanism of action for treating a medical condition. This is a concept that immediately makes you think of words like ‘innovation’, ‘novelty’, ‘potential’, ‘pioneering’ and ‘cutting-edge’ – all things that most pharmaceutical companies look for when considering areas of R&D to pursue and invest in. While they have the potential to boost the company’s pipeline and its profit, First-in-Class drugs also come with much greater risk and are definitely not guaranteed to succeed.
Editor’s pick August 2013 (EOID)July 17, 2013
Investigational drugs for coagulation disorders
(Pier Mannuccio Mannucci & Maria Elisa Mancuso)
August’s Editor’s pick is concerned with recent advances in the development of drugs for treating coagulation disorders, namely hemophilia. Hemophilia is a disorder of the blood-clotting system and while there’s no cure, most people with the disease can lead fairly normal lives and in the last few years many therapeutic improvements have been achieved.
Editor’s pick July 2013June 17, 2013Targeting angiopoietin-2 signaling in cancer therapy(Zeynep Eroglu, Cy A Stein & Sumanta K Pal)This timely review by Eroglu and colleagues looks at anti-angiogenic strategies in treating cancer and covers the role of angiopoietins in a variety of cancers such as ovarian, breast and gastrointestinal.
Protein kinase inhibitors: small molecules making a big impact in this special issue of EOIDMay 22, 2013Expert Opinion on Investigational Drugs would like to present a special issue dedicated to protein kinase inhibitors. These small molecules have potential to be active therapies in a wide variety of indications, from oncology through to neurology and beyond. Along with Guest Editor Tomi Sawyer, we explore some of the interesting drugs which fall into this class in this special issue of EOID.
Editor’s pick for May 2013 – Heat shock proteins give cancer a shockApril 30, 2013Increased antileukemic effects in human acute myeloid leukemia by combining HSP70 and HSP90 inhibitors, an original research article from Håkon Reikvam, Ina Nepstad, André Sulen, Bjørn Tore Gjertsen, Kimberley Joanne Hatfield & Øystein Bruserud is our pick of the May issue of Expert Opinion on Investigational Drugs from Editor-in-Chief Giuseppe Tonini.
MicroRNAs: a big deal for R&DMarch 28, 2013
Several Expert Opinion journals have published articles on miRNAs in the last year with more in the pipeline. This indicates just how important they are in all aspects of research and development and across a variety of therapy areas.
Editor’s pick for April 2013 – Sofosbuvir, a new HCV hope?March 25, 2013
Sofosbuvir, a nucleotide polymerase inhibitor, for the treatment of chronic hepatitis C virus infection from Prof K Rajender Reddy and colleagues, is our pick of the April issue of Expert Opinion on Investigational Drugs from our Editor-in-Chief Tonini Giuseppe.
Editor’s pick for March 2013February 26, 2013Radium-223 for the treatment of prostate cancer by Shaista Hafeez & Christopher Parker is our pick of the March issue from Editor-in-Chief Giuseppe Tonini.
Alpharadin (radium-223 chloride) is an experimental radiopharmaceutical under clinical evaluation to improve survival in patients with bone metastases from advanced cancer. The results in prostatic cancer makes this agent one of the most promising agents for the treatment of cancer patients in the near future.
Editor’s pick for February 2013February 7, 2013Novel immunomodulatory compounds in multiple myeloma by Neeraj Saini & Anuj Mahindra is our Editor’s pick for February from Giuseppe Tonini in Expert Opinion on Investigational Drugs.
Over the past 10 years, our understanding of the biology of melanoma and the body’s natural immuno-survelliance against this disease has increased dramatically. This knowledge has been translated into many new therapies. Indeed, this past 2-3 years, clinical trials testing several of these new treatments have demonstrated substantial tumor shrinkage, a prolonged remission interval and even improved overall survival.
Introducing Giuseppe Tonini as the new Editor-in-Chief of Expert Opinion on Investigational DrugsFebruary 6, 2013
We are very pleased to announce that Professor Giuseppe Tonini has recently accepted our invitation to become the new Editor-in-Chief of Expert Opinion on Investigational Drugs
Editorial highlight for January 2013January 7, 2013
Obstructive sleep apnea, a condition where you decrease your intake of air or stop breathing entirely when asleep, has been associated with signficant cardiovascular, neurological and metabolic disorders in paediatric suffers. As surgery is not as effective as previously believed, anti-inflammatory agents are being investigated as an alternative treatment for this common and underestimated condition.
Novel pharmacological approaches for treatment of obstructive sleep apnea in children is our editorial pick of the January issue of Expert Opinion on Investigational Drugs
Editorial higlight for December – exctiing new painkillers!November 12, 2012The editorial team would like to highlight a reviwe onNoradrenergic reuptake inhibition in the treatment of pain from Craig Hartrick, Professor, Biomedical Sciences and Anesthesiology at Oakland University as of special interest to the readers of Expert Opinion on Investigational Drugs.
Discontinued Drugs in 2011 – updateNovember 8, 2012Every year, Expert Opinion on Investigational Drugs publishes a short series of reviews looking at drugs grouped by specific indications, which have been discontinued in the previous year.
Continuing the series, we are happy to bring you a review on the area of oncology from Dr Robert Williams at Cancer Research UK.
Editorial pick for November 2012October 9, 2012New therapies in the treatment of melanoma by Diwakar Davar & John Munn Kirkwood is our editorial pick of the month for the November issue!
Editor’s Choice October 2012 – in the mood for melatoninSeptember 20, 2012Role of melatonin in mood disorders and the antidepressant effects of agomelatine by Venkataramanujam Srinivasan, Domenico De Berardis, Samuel D Shillcutt & Amnon Brzezinski is our pick of the month for October 2012.
Discontinued Drugs in 2011 seriesAugust 24, 2012Every year, Expert Opinion on Investigational Drugs publishes a short series of reviews looking at drugs grouped by specific indications, which have been discontinued in the previous year.
With reasons for discontinuation varying from failure to meet efficacy targets or safety endpoints, to decisions purely motivated by manufacturer finances, the range of drugs discussed offers a snapshot of the kind of drugs currently in the pipeline.
We are very happy to be able to bring you the first three articles in the Discontinued Drugs 2011 series, which are available online now.
Targeting memory processes with drugs to prevent or cure PTSD is our editorial pick for the September issue of EOIDAugust 13, 2012In their review, Targeting memory processes with drugs to prevent or cure PTSD, Cain, Maynard and Kehne discuss recent advances in our understanding of post-traumatic stress disorder (PTSD) and discuss the rationale in developing of new therapies to treat the neurobiological and psychological disorder.
Editor’s Choice July 2012 – Fighting the pain of endometriosisJune 26, 2012New trends for the medical treatment of endometriosis by Ana Luiza L Rocha, Fernando M Reis & Felice Petraglia is our editorial pick for July 2012.
Editor’s Choice June 2012 – Cancer therapy isn’t just about the tumourMay 14, 2012In treating cancer there are often two kinds of drugs used – the chemotherapy itself, aimed at preventing the development of the tumour; and also adjuvant therapies, aimed at reducing the side effects of these toxic compounds for the patient.
Melatonin uses in oncology: breast cancer prevention and reduction of the side effects of chemotherapy and radiation by Sanchez-Barcelo et al. is our editoral pick for June 2012.
New frontiers in female contraception – boldly going forward in the 21st centuryApril 18, 2012New frontiers in female contraception – boldly going forward in the 21st century A review of contraception in 2012 is our Editor’s pick for the May 2012 issue of EOID.
Let’s be clear – Expert Opinion on ethical publishingMarch 27, 2012In the interests of transparency, the editors would like to take the opportunity to update our readers on our ethical policies, and assure you that we take any breach of said policies very serieously, and will will investigate all such issues as fully as possible.
Editor’s Choice April 2012March 20, 2012Sabacitabine for cancer by Liu, Kantarjian and Plunkett is the Editor’s pick for April 2012.
Editor’s Choice March 2012February 20, 2012
The therapeutic potential of GPR119 agonists for type 2 diabetes is the Editor’s pick for March 2012.
Editor’s Choice February 2012January 17, 2012
Drugs in preclinical and early-stage clinical development for pancreatic cancer is our Editor’s pick for February 2012.
Expert Opinion Podcast with Angelica FasoloOctober 4, 2011
Dr Angelica Fasolo gives us an introduction to her recent paper, “Current and future directions in mTOR inhibitors development”. The mTOR signalling pathway has a central role in the regulation of several key cell processes and is frequently disregulated in tumor cells. Several mTOR inhibitors are currently undergoing phase III trials and Dr Fasolo discusses how they have been shown to have potential both as antiproliferative agents and in enhancing the efficacy of other anti-cancer drugs.